Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.

Saved in:
Bibliographic Details
Title: Venetoclax plus high-dose cytarabine and mitoxantrone as salvage treatment for relapsed or refractory acute myeloid leukaemia (RELAX): a multicentre, single-arm, phase 1/2 trial.
Authors: Ruhnke L; Department of Internal Medicine I, University Hospital Dresden, TUD Dresden University of Technology, Dresden, Germany., Schliemann C; Department of Medicine A, University Hospital Münster, Münster, Germany., Mikesch JH; Department of Medicine A, University Hospital Münster, Münster, Germany., Stelljes M; Department of Medicine A, University Hospital Münster, Münster, Germany., Fransecky L; Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany., Steffen B; Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt, Germany., Kaufmann M; Department of Hematology, Oncology and Palliative Care, Robert-Bosch-Krankenhaus, Stuttgart, Germany., Burchert A; Department of Internal Medicine, Hematology, Oncology and Immunology, University Hospital Marburg, Marburg, Germany., Rank A; Department of Internal Medicine II, Hematology and Oncology, University Hospital Augsburg, Augsburg, Germany., Hanoun M; Department of Hematology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany., Höllein A; Department of Internal Medicine III, Hematology and Oncology, Rotkreuzklinikum München, Munich, Germany., Kraus S; Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany., Schäfer-Eckart K; Department of Internal Medicine V, Klinikum Nürnberg, Paracelsus Medical University, Nuremberg, Germany., Hänel M; Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany., Haake A; Department of Internal Medicine I, University Hospital Dresden, TUD Dresden University of Technology, Dresden, Germany., Fiebig F; Department of Internal Medicine I, University Hospital Dresden, TUD Dresden University of Technology, Dresden, Germany., Kramer M; Department of Internal Medicine I, University Hospital Dresden, TUD Dresden University of Technology, Dresden, Germany., Zukunft S; Department of Internal Medicine I, University Hospital Dresden, TUD Dresden University of Technology, Dresden, Germany., Kunadt D; Department of Internal Medicine I, University Hospital Dresden, TUD Dresden University of Technology, Dresden, Germany., Middeke JM; Department of Internal Medicine I, University Hospital Dresden, TUD Dresden University of Technology, Dresden, Germany., Sockel K; Department of Internal Medicine I, University Hospital Dresden, TUD Dresden University of Technology, Dresden, Germany., Schetelig J; Department of Internal Medicine I, University Hospital Dresden, TUD Dresden University of Technology, Dresden, Germany., Platzbecker U; Department of Internal Medicine I, University Hospital Dresden, TUD Dresden University of Technology, Dresden, Germany., von Bonin M; Department of Internal Medicine I, University Hospital Dresden, TUD Dresden University of Technology, Dresden, Germany., Röhnert MA; Department of Internal Medicine I, University Hospital Dresden, TUD Dresden University of Technology, Dresden, Germany., Oelschlägel U; Department of Internal Medicine I, University Hospital Dresden, TUD Dresden University of Technology, Dresden, Germany., Wagenführ L; Department of Internal Medicine I, University Hospital Dresden, TUD Dresden University of Technology, Dresden, Germany., Thiede C; Department of Internal Medicine I, University Hospital Dresden, TUD Dresden University of Technology, Dresden, Germany; AgenDix, Dresden, Germany., Herold S; Institute of Pathology, Molecular Pathology, University Hospital Dresden, TUD Dresden University of Technology, Dresden, Germany., Poitz D; Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Dresden, TUD Dresden University of Technology, Dresden, Germany., Stölzel F; Department of Internal Medicine I, University Hospital Dresden, TUD Dresden University of Technology, Dresden, Germany; Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany., Baldus CD; Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany., Serve H; Department of Internal Medicine II, University Hospital Frankfurt, Frankfurt, Germany., Wermke M; Department of Internal Medicine I, University Hospital Dresden, TUD Dresden University of Technology, Dresden, Germany., Bornhäuser M; Department of Internal Medicine I, University Hospital Dresden, TUD Dresden University of Technology, Dresden, Germany., Röllig C; Department of Internal Medicine I, University Hospital Dresden, TUD Dresden University of Technology, Dresden, Germany. Electronic address: christoph.roellig@ukdd.de.
Source: The Lancet. Haematology [Lancet Haematol] 2026 Mar; Vol. 13 (3), pp. e157-e168.
Publication Type: Journal Article; Multicenter Study; Clinical Trial, Phase II; Clinical Trial, Phase I
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2352-3026
DOI:10.1016/S2352-3026(25)00358-8